Lactobacillus Sporogenes (Lactosporea)
A Clinically Documented Pro-Biotic for Nutritional Use
Viadimir Badmaev, M.D.,Ph.D. and Muhammed Majeed, Ph.D.
Ayurveda, or "the
Science of Life", was born in India during pre Buddhist times.
This system of medicine is particularly well known for the attention
it pays to the digestive tract, digestive processes and the therapies
originating in food; hence the Indian saying, "food is your medicine".
The role of supplemental probiotics in maintaining a healthy pool of friendly bacteria in the body is an important issue. We are learning that probiotics can be sloughed off by numerous factors such as: poor nutrition, hectic and stressful pace of life, the intake of certain drugs like antacids, antibiotics, laxatives, and even non-steroidal anti-inflammatory drugs (NSAIDs). However, not just any product labeled "probiotic" is suitable for supplemental use.
Ideal probiotic should have these characteristics:
1) Produce L (+) lactic acid, which is the beneficial form of lactic acid. That is in distinction to D (-) lactic acid, which has been found to induce metabolic acidosis.
2) Be stable at room temperature, and resistant to the action of gastric acid.
3) Have the capability of easy and non-invasive proliferation in the gut.
4) Lack potential for mating with pathogenic bacteria.
Lactobacillus Sporogenes is an example of a bacteria that meets these characteristics, especially as a sporiferous (producing cocoon-like structures, spores, sheltering life bacteria) for of probiotic.
This unique probiotic offers beneficial lactobacilli which have natural protection from the negative factors due to manufacturing such as compression and heat, and from possible interaction with other ingredients in multi-component products, for example, vitamins, minerals, amino acids, proteins, fatty acids and sugars, especially fructooligosaccharides. Based on accelerated stability tests (incubations at 45°C. 80% relative humidity for 90 days), this probiotic can provide up to 95% live lactobacilli after three years storage at room temperature.
|L. Sporogenes was first isolated and described in 1993 by Russian scientists L.M. Horowitz-Wlassowa and N.W. Nowotelnow (Zentbl. F. Bakt., 1933) and the name was accepted in the fifth edition of Bergey's Manual of Determinative Bacteriology which in the USA is the system of bacterial classification that is routinely used. L. Sporogenes produces only L(+) lactic acid and proliferates within the gastrointestinal tract in an non-invasive way characteristic of beneficial gastro-intestinal residents such as Lactobacillus Acidophilus and Bifidobacterium Bifidum. The non-invasive pattern of proliferation of L. Sporogenes has been documented in a human experiment (Mashimo et al. 1964). Oral supplementation with L. Sporogenes for several days colonized this probiotic in the human gut flora, however on the sixth day after the discontinuation of the therapy the supplement probiotic was entirely eliminated. Therefore, probiotic supplementation may be required almost daily in certain age groups, especially with what is now known about the adverse affects that poor diet, fast paced living and various OTC and prescription drugs have on our digestive systems.|
|An L. Sporogenes product has received approval for the Japanese Ministry of Health and Welfare, LacbonÔ tablets are indicated for improvement in symptoms caused by abnormalities in the intestinal flora or in dysbiosis. Clinical trials with LacbonÔ tablets have been conducted in Japan in 19 independent health care institutions and been shown effective in treating diarrhea due to acute or chronic gastroenteritis, mal-digestion, infantile diarrhea and constipation (Hattori, Z. et al. 1965 and Mashita, H. et al. 1964).|
|Other clinical studies with L. Sporogenes have also been conducted. A study evaluating its effectiveness in treating 17 patients with type II hyperlipidaemia (Mohan, J.C. et al. 1990). The patients were given 120 million spores of L. Sporogenes, three times daily for a period of two weeks. Treatment with L. Sporogenes resulted in a significant reduction in the total cholesterol levels (330 mg/dl vs. 226 mg/dl, LDL-cholesterol levels (267 mg/dl vs. 173 mg/dl) and a small but significant increase in HDL-cholesterol levels (43.6 mg/dl vs. 46.8 mg/dl). Altherogenic lipid ratios were also significantly reduced with no change in serum triglycerides.|
|Another clinical study has found that L. Sporogenes is effective in treating patients with nonspecific vaginitis caused by gram negative bacteria. In this case, each of the 44 patients received 150 million spores per tablet in suppository form, twice daily for two weeks. Complete relief of the condition was accomplished in 91% of the cases and partial in the remaining nine percent (Sanicholkar, P.C. and M.S. Sali, Department of Obstetrics and Bynaecology, Medical college, Pune India).|
|In general the recommended dose of Lactospore for adults is 100-200 million spores, three times a day. In one study, L. Sporogenes taken at a dose of 360-million spores/ day resulted in a lowering blood cholesterol over a period of three months. The significant therapeutic effect in treating diarrhea due to acute or chronic gastroenteritis was accomplished with 50-200 million spores of L. Sporogenes per day within a few days.|
|The supplemental use of probiotics that meet the above mentioned characteristics , like that of L. Sporogenes, will likely experience and increase in use as their basic health benefits become more fully understood and accepted by the medical community as well as the average consumer.|
|In Lactospore®, the long standing and time proven health practices employed in Ayurveda, are combined with the advantage of a room temperature-stable and clinically tested probiotic bacteria. There is truth in the saying that "everything old is new again."|
Z et al. 1965. J. Bacterial. 90:541:
H. et al. 1964. J. New remedies & Clinics. 13:977
et al. 1964 New Drugs and Clinics. 13:9.
J.C. et al. 1990 Ind. J. Med. Res. 92: 431-432
Sanicholkar, PC and Sai, M.S. Dept. Obstetrics and Gynecology, Medical College, India.
Vladimir Badmaev, M.D., Ph.D., is trained in clinical and anatomical pathology. With a Ph.D. in the field of immunopharmacology. An author of many articles and books on traditional Ayudddrvedic and Tibetan medicine, he is the Vice-President of Scientific and Medical Affairs for Sabinsa.
Muhammed Majeed, Ph.D., has a doctorate in industrial pharmacy. With over 15 years of pharmaceutical research experience in the US with leading companies such as Pfizer, Inc., Charter Wallace and Paco Research, Dr. Majeed is knowledgeable on the pharmacology of herbal medicines used in Ayurveda. He is the President and CEO of Sabinsa.
Natural Health Product Report, juin/juillet, 1999
These products have not been evaluated by the Food & Drug Administration. This is provided for informational use only and is not intended to replace the advice of a licensed professional. This information is not intended to diagnose, treat, cure or prevent any disease, disorder, pain, injury, deformity, or physical or mental condition This notice is required by the Federal Food, Drug and Cosmetic Act.